Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Spark Therapeutics, Inc. (ONCE) on Behalf of Stockholders and Encourages ONCE Investors to Contact the Firm
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Spark Therapeutics, Inc. (NASDAQ: ONCE) on behalf of stockholders concerning the proposed acquisition of the company by Roche Holding AG.
Click here to participate in the action.
Pursuant to the proposed transaction, announced on February 25, 2019 and valued at $4.3 billion, Spark stockholders will receive $114.50 in cash for each share of Spark common stock owned. The investigation focuses on whether Spark and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Spark shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 308-1869, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Spark please go to https://bespc.com/once/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.